For example, brodalumab, an IL17RA antagonist, has been used to treat moderate to severe plaque psoriasis (49); miglustat, a glycosphingolipid synthesis inhibitor, has been used in diseases in which the enzyme glucocerebrosidase is deficient, such as Gaucher disease (50) and cystic fibrosis (51); and elosulfase alfa helps correct N-acetylglucosamine-6-sulfate sulfatase enzyme deficiency in mucopolysaccharidosis type IV (52). Here, IL17RA is linked to cystic fibrosis.